FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Leverone Jason A.
2. Issuer Name and Ticker or Trading Symbol

MIRAGEN THERAPEUTICS, INC. [ MGEN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CFO, Treasurer & Secretary
(Last)          (First)          (Middle)

C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

3/13/2020
(Street)

BOULDER, CO 80301
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/13/2020  M  11249 A$0.57 48829 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $0.57 3/13/2020  M     11249   (2)3/15/2020 Common Stock 11249 $0.00 0 D  

Explanation of Responses:
(1) Includes 1,250 shares acquired under the Miragen Therapeutics, Inc. 2015 Employee Stock Purchase Plan on February 21, 2020.
(2) The option is fully vested and exercisable. The option expires ten years after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Leverone Jason A.
C/O MIRAGEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
BOULDER, CO 80301


CFO, Treasurer & Secretary

Signatures
/s/ Kurtis Zinger, as Attorney-in-Fact for Jason A. Leverone3/17/2020
**Signature of Reporting PersonDate

Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Miragen Therapeutics Charts.
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Miragen Therapeutics Charts.